

July 24, 2019

Listing Department  
**BSE LIMITED**  
P J Towers, Dalal Street, Fort,  
Mumbai-400 001

Code: 532 321

Listing Department  
**NATIONAL STOCK EXCHANGE OF INDIA LIMITED**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E),  
Mumbai-400 051

Code: CADILAHC

Re.: Press Release

Dear Sir / Madam,

Please find enclosed a copy of press release dated July 24, 2019 titled "Zydus has launched Ramelteon Tablets in the US upon receiving final approval from the USFDA".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,  
For, **CADILA HEALTHCARE LIMITED**

  
**DHAVAL N. SONI**  
**COMPANY SECRETARY**



Encl.: As above

## **Zydus has launched Ramelteon Tablets in the US upon receiving final approval from the USFDA**

*Ahmedabad, 24 July, 2019*

Zydus Cadila announced the Day – 1 launch of Ramelteon Tablets (US RLD –Rozerem Tablets), 8 mg upon receiving the final approval from the USFDA. Ramelteon is a sedative, also called a hypnotic. It works by affecting certain substances in the body that help regulate the "sleep-wake cycle." Ramelteon is used to treat insomnia that is associated with having trouble falling asleep. The drug will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad.

The group now has 270 approvals and has so far filed over 360 ANDAs since the commencement of the filing process in FY 2003-04.

### **About Zydus Cadila**

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.

\*\*\*